Session

Localised prostate cancer: Innovative strategies in active surveillance and focal therapy

Poster Session 66

  • Location:
    Room Madrid (Hall B2, level 0)
  • Chairs:
     H.U. Ahmed, London (GB)
     J-L. Descotes, Grenoble (FR)
     G. Giannarini, Udine (IT)
  • Aims and objectives of this session

    The session focuses on novel strategies in active surveillance and focal therapy for prostate cancer

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
829
Multiparametric MRI features that poorer mid-term outcomes in active surveillance patients

By: Sanguedolce F.1, Petralia G.2, Sokhi H.3, Tagliabue E.4, Anyamene N.5, Hellawell G.6, Padhani A.R.7

Institutes: 1Northampton General Hospital NHS Trust, Dept. of Urology, Northampton, United Kingdom, 2Istituto Europeo di Oncologia, Dept. of Urology, Milan, Italy, 3Hillingdon & Mount Vernon Hospital, Dept. of Radiology, London, United Kingdom, 4Istituto Europeo di Oncologia, Division of Epidemiology and Biostatistics, Milan, Italy, 5Mount Vernon Hospital, Dept. of Oncology, London, United Kingdom, 6Northwick Park Hospital, Dept. of Urology, London, United Kingdom, 7Mount Vernon Cancer Centre, Paul Strickland Scanner Centre, London, United Kingdom

830
Multiparametric MRI predicts adverse pathological prostate cancer features in patients eligible for active surveillance

By: Boesen L.1, Nørgaard N.1, Loegager V.2, Jakobsen J.1, Bisbjerg R.1, Thomsen H.2, Jakobsen H.1

Institutes: 1Herlev Hospital, Dept. of Urology, Herlev, Denmark, 2Herlev Hospital, Dept. of Radiology, Herlev, Denmark

831
Multiparametric-MRI, PCA3 and PHI in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance

By: Porpiglia F.1, De Luca S.1, Manfredi M.1, Mele F.1, Russo F.2, Sottile A.3, Serra N.1, Fiori C.1

Institutes: 1San Luigi Gonzaga Hospital, University of Turin, Dept. of Urology, Orbassano, Italy, 2Candiolo Cancer Insititute, Dept. of Radiology, Candiolo, Italy, 3Candiolo Cancer Insititute, Dept. of Laboratory Medicine, Candiolo, Italy

832
Molecular profiling of prostate cancer derived from serial MRI targeted prostate biopsy in men on active surveillance

By: Palapattu G.2, Cani A.K.3, Hoevelson D.3, Mehra R.3, Montgomery J.S.1, Morgan T.1, Salami S.1, Tomlins S.A.3, Marks L.S.4

Institutes: 1University Of Michigan, Dept. of Urology, Ann Arbor, United States of America, 2University of Michigan, Dept. of Urology, Ann Arbor, United States of America, 3University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, 4University of California, Los Angeles, Dept. of Urology, Los Angeles, United States of America

833
Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic pro-static enlargement: A risk-adaptive strategy for the era of active surveillance

By: Koo K.C.1, Lee K.S.1, Lee D.H.2, Rha K.H.1, Hong S.J.1, Bang W.J.3, Chung B.H.1

Institutes: 1Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, 2Busan National University College of Medicine, Dept. of Urology, Busan, South Korea, 3Hallym University College of Medicine, Dept. of Urology, Seoul, South Korea

834
Standardization in definitions in focal therapy for prostate cancer: Report from a Delphi consensus project

By: Postema A.1, De Reijke T.1, Ukimura O.2, Van Den Bos W.1, De La Rosette J.1

Institutes: 1AMC University Hospital, Dept. of Urology, Amsterdam, The Netherlands, 2Keck School of Medicine, University of Southern California, Dept. of Urology, Los Angeles, United States of America

835
High intensity focused ultrasound hemiablation versus MRI guided ‘lesion only’ ablation of prostate cancer – genito-urinary functional outcomes and complications

By: Sivaraman A., Sanchez-Salas R., Linares Ospinos E., Perez Regetti J., Russo A., Armando Hernandez Palacios G., Barret E., Validire P., Rozet F., Galiano M., Cathelineau X.

Institutes: Institute Mutualiste Montsouris, Dept. of Urology, Paris, France

836
MRI-US fusion guided high-intensity focused ultrasound with Focal-One® system: Impact on PSA, complications and genito-urinary functions during initial experience

By: Perez Reggeti J.I., Sanchez-Salas R., Linares Espinos E., Sivaraman A., Russo A., Hernandez Palacios G., Barret E., Galiano M., Rozet F., Prapotnich D., Cathala N., Mombet A., Cathelineau X.

Institutes: Institute Mutualiste Montsouris, Dept. of Urology, Paris, France

837
Intraprostatic spatial distribution of prostate cancer: A pre versus post HIFU comparison based on 15.000 biopsies

By: Thüroff S.1, Chaussy C.2

Institutes: 1Klinikum Harlaching, Dept. of Urology, Munich, Germany, 2St. Josephs Klinik, Dept. of Urology, Regensburg, Germany

838
Magnetic resonance imaging-guided transurethral ultrasound prostate ablation in patients with localized prostate cancer: 12-Month outcomes of a prospective phase I clinical trial

By: Billia M.1, Pahernik S.2, Relle J.3, Popeneciu I.V.2, Kuru T.2, Hafron J.3, Romagnoli C.4, Burtnyk M.5, Schlemmer H-P.2, Chin J.L.4

Institutes: 1London Health Sciences Center University of Western Ontario, Dept. of Urology and Radiology, London, Canada, 2German Cancer Research Center (DKFZ), Dept. of Urology and Radiology, Heidelberg, Germany, 3Beaumont Health System, Dept. of Urology and Radiology, Royal Oak, United States of America, 4London Health Sciences Center University of Western Ontario, Dept. of Urology and Radiology, London Ontario, Canada, 5Profound Medical Inc., Dept. of Engineering, Toronto, Canada

839
A prospective development study evaluating focal irreversible electroporation in men with localised prostate cancer: The NEAT trial

By: Valerio M.1, Dickinson L.1, Ali A.2, Ramachadran N.3, Donaldson I.1, McCartan N.1, Freeman A.4, Ahmed H.1, Emberton M.1

Institutes: 1UCLH NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 2UCL, Dept. of Mental Health Sciences, London, United Kingdom, 3UCLH NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, 4UCLH NHS Foundation Trust, Dept. of Pathology, London, United Kingdom

840
Can small lesions of Gleason 3+4 be left untreated in focal therapy? Analysis of radical prostatectomy specimens

By: Kanao K., Kajikawa K., Kobayashi I., Muramatsu H., Morinaga S., Nishikawa G., Yoshizawa T., Kato Y., Watanabe M., Nakamura K., Sumitomo M.

Institutes: Aichi Medical University, Dept. of Urology, Nagakute, Japan

841
Medium term outcomes following focal HIFU for the treatment of non-metastatic prostate cancer: A UK registry analysis of 625 cases

By: Guillaumier S.1, Hamid S.1, Charman S.1, Van Der Meulen J.1, McCartan N.1, Shah K.1, Hindley R.2, Nigam R.3, Dudderidge T.4, Afzal N.5, Cornaby A.5, Lewi H.6, Persad R.7, Moore C.1, Virdi J.8, Arya M.8, Emberton M.1, Ahmed H.U.1

Institutes: 1University College London, Dept. of Surgery and Interventional Sciences, London, United Kingdom, 2Basingstoke Hospital, Dept. of Urology, Basingstoke, United Kingdom, 3Royal Surrey County Hospital, Dept. of Urology, Surrey, United Kingdom, 4Southampton Hospital, Dept. of Urology, Southampton, United Kingdom, 5Dorset County Hospital, Dept. of Urology, Dorset, United Kingdom, 6Springfield Hospital, Dept. of Urology, Chelmsford, United Kingdom, 7North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom, 8Princess Alexandra Hospital, Dept. of Urology, Essex, United Kingdom

842
An open, single dose, anti-tumour effect study of 2-hydroxyflutamide as a controlled release product (Liproca® Depot) injected into the prostate in patients with localized prostate cancer

By: Tammela T.1, Bjartell A.2, Häggman M.3

Institutes: 1Tampere University Hospital, Dept. of Surgery, Tampere, Finland, 2Skåne University Hospital, Dept. of Urology, Malmö, Sweden, 3Uppsala University Hospital, Dept. of Urology, Uppsala, Sweden